TYVYT

  •   George Lundberg, MD

    Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

    In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

    .